Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Samantha J SeitterRichard M SherryJames C YangPaul F RobbinsMackenzie L ShindorfAmy R CopelandChristine T McGowanMonica EpsteinThomas E SheltonMichelle M LanghanZulmarie FrancoDavid N DanforthDonald E WhiteSteven A RosenbergStephanie L GoffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Patients previously treated with PD-1 or MAPK inhibition are significantly less likely to develop durable objective responses to ACT-TIL. While ACT-TIL is currently being investigated for treatment-refractory patients, it should also be considered as an initial treatment option for eligible patients with metastatic melanoma.